Domperidone use in Parkinson's Disease and Risk of Serious Cardiac Events

Project number: 
Approval date: 
Tuesday, March 18, 2014
Principal Investigator: 
University of British Columbia (UBC)
Funding Agency: 
Canadian Institutes of Health Research(CIHR)
Datasets requested: 
Home and Community Care (BC Ministry of Health)
Consolidation file (BC Ministry of Health)
consolidation - census geocodes
Consolidation registry (Ministry of Health)
Hospital Separations (BC Ministry of Health)
Consolidation - demographic (Ministry of Health)
Deaths (BC Vital Statistics Agency)
Medical Services Plan (BC Ministry of Health)
Research objective: 

The general objective is to assess the risk of serious cardiac events associated with the use of domperidone in a population-based cohort of patients with Parkinsons disease. Specifically, the objectives of this study are to:

1) to assess the risk of serious ventricular tachyarrhythmia and sudden cardiac death associated with the use of domperidone compared to no use in patients with Parkinsons disease,

2) to assess whether the risk of ventricular arrhythmia and sudden cardiac death increases with the dose of domperidone in patients with Parkinsons disease.


1) The use of domperidone increases the risk of serious cardiac events. The risk is increased within days after exposure and decreases rapidly after cessation of use.

2) A higher dose of domperidone (>30 mg per day) is associated with an increased risk of serious cardiac events compared to a lower dose.


Journal Publication

  • Renoux, C., Dell'Aniello, S., Khairy, P., Marras, C., Bugden, S., Turin, T. C., Blais, L., Tamim, H., Evans, C., Steele, R., Dormuth, C., Ernst, P., and the Canadian Network for Observational Drug Effect Studies (CNODES) investigators (2016) Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease. Br J Clin Pharmacol, 82: 461–472. doi: 10.1111/bcp.12964.

Page last revised: May 13, 2019